Abstract C001: Application of CRISPR–Cas9 technology in the treatment of chronic lymphocytic leukemia with mutant P53 gene
TL;DR
It is demonstrated that technology CRISPR–Cas9 gene editing holds significant promise as a therapeutic strategy for TP53-mutant CLL by enabling precise gene correction of functional replacement.
Abstract
The status of P53 suppressor gene, from double strands DNA, can be tested in cooperation with partners at IARC (International Agency for Research on Cancer). In solid malignant tumors, the P53 gene is mutated or deleted in approximately 50% of all tumors, but in Chronic Lymphocytic Leukemia, (CLL), P53 gene aberrations are ranging from 5-10% at the time of diagnosis. This study looks at using CRISPR–Cas9 gene-editing technology to fix mutations in the white blood cells of patients with CLL with mutant P53 Gene. It’s a promising new way to treat this complex disease. CRISPR–Cas9 works like a GPS for DNA. It uses a guide RNA (gRNA) to lead a specific enzyme to a target spot in the genetic code. Once there, the enzyme cuts the DNA to disable or fix the TP53 gene. This guide is usually made of two parts (crRNA and tracrRNA), but researchers found they can combine them into one single, efficient "chimeric" RNA molecule. While the natural two-part system works well, using a single-guide system is much easier for programming DNA edits. The system is very precis and it only cuts if it finds a specific "docking code" (called a PAM) next to the target. By creating these precise breaks, we hope to replace the mutated P53 genes in CLL cells with healthy ones. Basically, CRISPR–Cas9 acts like "molecular scissors," allowing scientists to cut, paste, or delete DNA. It’s a game changer for the future of genetic medicine. This study demonstrates that technology CRISPR–Cas9 gene editing holds significant promise as a therapeutic strategy for TP53-mutant CLL by enabling precise gene correction of functional replacement. Aurelian Udristioiu, Manole Cojocaru. Application of CRISPR–Cas9 technology in the treatment of chronic lymphocytic leukemia with mutant P53 gene [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Bridging Discovery and Clinical Impact in Pediatric Cancer; 2026 Sep 22-25; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_1):Abstract nr C001.
